… actors purposively engage in the disrupting of institutions. … research and organisational
research, cholesterol lowering drugs, … The food industry invested in research and development to …

… on the role of the pharmaceutical industry, we aim to show how … other actors and entities that
are pivotal for the transformation of … gave rise to an increased focus on cholesterol lowering …

… The aim of these is to promote development of national … of statin therapy for cholesterol
lowering and reduction of CVD risk… facilities with testing labs may be prohibitively long, acting as a …

… of considering a cholesterol-lowering treatment strategy in … BP (SBP) and a slower rise in
SBP with age than people without … ensure that these short-acting agents would be active during …

… Further studies at Merck led to the development of the first HMG-CoA reductase inhibitor, …
long-acting statin every other day or 2 times per week has been employed. Short acting statins …

… This has prompted the development of new LDL-C lowering drugs in the hope to reduce …
C, lipoprotein (a)), intravascular inflammation or acting by other mechanisms also have a role in …

… It has been known for some time that besides acting on the LDL receptor, SREBPs act to
upregulate protease proprotein convertase subtilisin/kexin type 9 (PCSK9). The protease …

… or contemplating taking a cholesterol-lowering drug, we urge … is a minor player in the
development of heart disease and that … It’s got a cast of characters ranging from the obnoxious and …

… , placebo-controlled study that enrolled 269 patients with a history of statin intolerance and
… Treatment with bempedoic acid was well tolerated as rates of treatment-emergent adverse …

… activity), intensive cholesterol-lowering, and blood pressure (… The development of heart failure
also relates to the degree of … several international drug regulatory agencies to mandate the …